El receptor NKG2D en la frontera de la inmunovigilancia y la carcinogénesis

El receptor NKG2D en la frontera de la inmunovigilancia y la carcinogénesis

El sistema inmune es capaz de realizar la detección y eliminación de células transformadas por un mecanismo fisiológico conocido como inmunovigilancia. En este proceso participa el receptor activador NKG2D presente en linfocitos T y células NK, ambos de suma relevancia en la inmunovigilancia contra...

Full description

Bibliographic Details
Main Author:	Jorge Flavio Mendoza Rincón
Format:	Article
Language:	English
Published:	Universidad Colegio Mayor de Cundinamarca 2014-07-01
Series:	NOVA
Subjects:	Carcinogénesis Inmunovigilanci NKG2D NKG2DL
Online Access:	https://revistas.unicolmayor.edu.co/index.php/nova/article/view/248

Similar Items

NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
by: Dominik Schmiedel, et al.
Published: (2018-09-01)

NKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications
by: Jagoda Siemaszko, et al.
Published: (2021-06-01)

INHIBITION OF THE NKG2D ACTIVATING RECEPTOR EXPRESSION ON CYTOTOXIC LYMPHOCYTES BY RECOMBINANT MICA PROTEIN
by: E. V. Abakushina, et al.
Published: (2017-01-01)

Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
by: Adeline Raynaud, et al.
Published: (2021-01-01)

The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
by: Ge Tan, et al.
Published: (2023-08-01)

NKG2D Polymorphism in Melanoma Patients from Southeastern Spain
by: Lourdes Gimeno, et al.
Published: (2019-03-01)

NKG2D Ligand Shedding in Response to Stress: Role of ADAM10
by: Alessandra Zingoni, et al.
Published: (2020-03-01)

Romidepsin Enhances the Killing Ability of NKG2D-CAR-T Cells through Enhanced Expression of NKG2DL against Ovarian Cancer Cells
by: Liang Wang, et al.
Published: (2022-09-01)

NKG2D and Its Ligands: “One for All, All for One”
by: Alessandra Zingoni, et al.
Published: (2018-03-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2019-05-01)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
by: Xin Jin, et al.
Published: (2023-12-01)

NKG2C+NKG2A− Natural Killer Cells are Associated with a Lower Viral Set Point and may Predict Disease Progression in Individuals with Primary HIV Infection
by: Meichen Ma, et al.
Published: (2017-09-01)

A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression
by: Trever T Greene, et al.
Published: (2016-11-01)

Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
by: Richard Baugh, et al.
Published: (2020-12-01)

Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response
by: Stipan eJonjic
Published: (2011-12-01)

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome
by: Anna Seller, et al.
Published: (2024-04-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
by: Ilona Hagelstein, et al.
Published: (2021-04-01)

Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression
by: Amber B. Jones, et al.
Published: (2022-05-01)

Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections
by: Luis Romero-Martín, et al.
Published: (2022-11-01)

Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy
by: Jin Wang, et al.
Published: (2022-07-01)

Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer
by: Chen J, et al.
Published: (2015-12-01)

The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
by: Florencia Secchiari, et al.
Published: (2022-12-01)

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
by: Tobias Zöller, et al.
Published: (2018-03-01)

Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2Cnull Human Immunodeficiency Virus-Infected Individuals
by: Emilie M. Comeau, et al.
Published: (2019-03-01)

KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP
by: Reem Alkhayer, et al.
Published: (2023-05-01)

Significance of HLA-E and its two NKG2 receptors in development of complications after allogeneic transplantation of hematopoietic stem cells
by: Jagoda Siemaszko, et al.
Published: (2023-10-01)

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
by: Lina Driouk, et al.
Published: (2020-12-01)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
by: Thornton W Thompson, et al.
Published: (2017-12-01)

NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells
by: Marta Ibáñez-Navarro, et al.
Published: (2023-10-01)

Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro
by: Mahdi Zarei, et al.
Published: (2023-10-01)

Tumor-derived CSF-1 induces the NKG2D ligand RAE-1δ on tumor-infiltrating macrophages
by: Thornton W Thompson, et al.
Published: (2018-05-01)

NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer
by: Sophie Curio, et al.
Published: (2023-03-01)

MICA-specific nanobodies for diagnosis and immunotherapy of MICA+ tumors
by: Elisha R. Verhaar, et al.
Published: (2024-03-01)

Leveraging NKG2D Ligands in Immuno-Oncology
by: Mercedes Beatriz Fuertes, et al.
Published: (2021-07-01)

Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease
by: Daniel Fernández-Soto, et al.
Published: (2024-02-01)

Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys
by: Peter B. Rupert, et al.
Published: (2024-04-01)

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
by: Polina Kaidun, et al.
Published: (2023-08-01)

Molecular bases for the regulation of NKG2D ligands in cancer
by: Leticia eHuergo-Zapico, et al.
Published: (2014-03-01)

T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells
by: Dong Yang, et al.
Published: (2019-07-01)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
by: Christine Koch, et al.
Published: (2017-11-01)